Loading organizations...
Key people at Altium Capital.
Altium Capital Management is an investment firm providing growth capital to healthcare companies. It focuses on private and public entities developing novel human health technologies. The firm targets therapeutics across all development stages, identified via rigorous due diligence for their long-term potential.
Jacob Gottlieb, MD, CFA, PRM, founded Altium Capital Management in 2017, leveraging two decades of healthcare investment expertise. He previously established Visium Asset Management in 2005, building and leading high-performing healthcare equity teams. This deep experience in funds provided the core insight for Altium's dedicated sector focus.
Altium Capital partners with private and public healthcare companies, offering financial and strategic support through multiple financing rounds. Its long-term vision is to advance human health by nurturing innovation. The firm helps portfolio companies secure further capital, guided by principles of integrity and collaborative industry improvement.
Key people at Altium Capital.
Altium Capital has 3 tracked investments across 3 companies. The latest tracked deal is $75.0M Series B in Antios Therapeutics in November 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 1, 2021 | Antios Therapeutics | $75.0M Series B | Epiq Capital Group, Craig Gordon | Domain Associates, Pontifax Venture Capital, Adage Capital Management, Aisling Capital, Amzak Health, Avego Bioscience Capital, CAM Capital, Delos Capital, Granite Point Capital, GRA Venture Fund, Heartland Healthcare Capital, Lifesci Venture Partners, Lumira Ventures, RA Capital Management, Sixty Degree Capital, Soleus Capital |
| Feb 12, 2021 | 3-V Biosciences | $80.0M Other Equity | — | Ascletis, HM Capital, Invus, Beth Seidenberg, Matt McAviney, PFM Health Sciences, Rock Springs Capital |
| Feb 10, 2021 | Hyperfine | $90.0M Series D | — | Axiom Associates, Colle Capital, GV, Huami, LSS, Nextrans |
